Verition Fund Management LLC
Institutional investor · Portfolio as of Q3 2019
Top Holdings1,011 positions
Allergan PLC | 1.4M | $232.1M | 6.4% | — | — | — | Increased — |
Bank of Nova Scotia/The | 4M | $227.4M | 6.3% | — | — | — | Increased — |
Canadian Imperial Bank of Comm | 2M | $165.1M | 4.6% | — | — | — | Increased — |
TransCanada Corp | 3M | $155.4M | 4.3% | — | — | — | Unchanged — |
Celgene Corp | 1.4M | $136.1M | 3.8% | — | — | — | Increased — |
Allergan PLC | 424,000 | $71.1M | 2.0% | — | — | — | Increased — |
Occidental Petroleum Corp | 1.5M | $68.4M | 1.9% | — | — | — | Increased — |
Celgene Corp | 638,800 | $63.4M | 1.7% | — | — | — | Increased — |
Suncor Energy Inc | 2M | $63.2M | 1.7% | $24.79 | 0.00% | 3 qtrssince 2019-Q1 | Increased 75 |
Toronto-Dominion Bank/The | 1M | $57.7M | 1.6% | — | — | — | New — |
HSBC Holdings PLC | 1.4M | $53.5M | 1.5% | $27.12 | -0.27% | 3 qtrssince 2019-Q1 | Increased 75 |
MELLANOX TECHNOLOGIES LTD | 484,800 | $53.1M | 1.5% | — | — | — | Increased — |
AbbVie Inc | 631,500 | $47.1M | 1.3% | — | — | — | Increased — |
Centene Corp | 889,200 | $38.5M | 1.1% | — | — | — | Decreased — |
Vodafone Group PLC | 1.9M | $38.1M | 1.0% | $10.96 | +14.06% | 4 qtrssince 2018-Q4 | Decreased 0 |
| 20.6M | $33.1M | 0.9% | — | — | 4 qtrssince 2018-Q4 | Decreased 0 | |
Marathon Petroleum Corp | 544,400 | $33.1M | 0.9% | — | — | — | New — |
MSG NETWORK INC | 2M | $32.8M | 0.9% | — | — | — | New — |
| 21.8M | $32.4M | 0.9% | — | — | — | Unchanged 0 | |
| 27.9M | $31.9M | 0.9% | — | — | 4 qtrssince 2018-Q4 | Decreased 0 |
Verition Fund Management LLC manages $3.6B across 1011 positions as of Q3 2019. Top holdings: AGN puts (6.4%), BNS calls (6.3%), CM calls (4.6%). Fund DNA: Diversified Scout. HoldingsIntel Score: 1.5/5.0.
Active quarter - 378 new positions, 427 exits, 202 increased. Top move: SU (INCREASED, conviction 75). Portfolio: $3.6B across 1011 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR